{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T03:07:37Z","timestamp":1792292857658,"version":"4.4.0"},"reference-count":72,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2015,2,1]],"date-time":"2015-02-01T00:00:00Z","timestamp":1422748800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100005010","name":"Italian Association for Cancer Research","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["cancertreatmentreviews.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2015,2]]},"DOI":"10.1016\/j.ctrv.2014.12.013","type":"journal-article","created":{"date-parts":[[2015,1,6]],"date-time":"2015-01-06T17:36:07Z","timestamp":1420565767000},"page":"114-121","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":156,"title":["PD-1 blockade therapy in renal cell carcinoma: Current studies and future promises"],"prefix":"10.1016","volume":"41","author":[{"given":"F.","family":"Massari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Santoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Ciccarese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Santini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Alfieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Martignoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Brunelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Piva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Berardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Montironi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Porta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Cascinu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Tortora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctrv.2014.12.013_b0005","doi-asserted-by":"crossref","first-page":"5576","DOI":"10.1200\/JCO.2006.08.3774","article-title":"Immunotherapy for renal cell cancer","volume":"24","author":"Yang","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2014.12.013_b0010","first-page":"165","article-title":"Renal cell carcinoma-induced immunosuppression: an immunophenotypic study of lymphocyte subpopulations and circulating dendritic cells","volume":"27","author":"Porta","year":"2007","journal-title":"Anticancer Res"},{"key":"10.1016\/j.ctrv.2014.12.013_b0015","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.4161\/onci.21356","article-title":"Intratumoral alterations of dendritic-cell differentiation and CD8(+) T-cell anergy are immune escape mechanisms of clear cell renal cell carcinoma","volume":"1","author":"Noessner","year":"2012","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.ctrv.2014.12.013_b0020","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"Blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.ctrv.2014.12.013_b0025","doi-asserted-by":"crossref","first-page":"3887","DOI":"10.1002\/j.1460-2075.1992.tb05481.x","article-title":"Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death","volume":"11","author":"Ishida","year":"1992","journal-title":"EMBO J"},{"key":"10.1016\/j.ctrv.2014.12.013_b0030","doi-asserted-by":"crossref","first-page":"4917","DOI":"10.1158\/1078-0432.CCR-12-1972","article-title":"Molecular pathways: co-expression of immune checkpoint molecules: signaling pathways and implications for cancer immunotherapy","volume":"19","author":"Nirschl","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.ctrv.2014.12.013_b0035","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1158\/2326-6066.CIR-13-0133","article-title":"PD-1 expression on peripheral blood cells increases with stage in renal cell carcinoma patients and is rapidly reduced after surgical tumor resection","volume":"2","author":"MacFarlane","year":"2014","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.ctrv.2014.12.013_b0040","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.coi.2007.04.012","article-title":"PD-1 and its ligands in T-cell immunity","volume":"19","author":"Keir","year":"2007","journal-title":"Curr Opin Immunol"},{"issue":"8","key":"10.1016\/j.ctrv.2014.12.013_b0045","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1093\/intimm\/dxq049","article-title":"PD-L1 and PD-L2 differ in their molecular mechanisms of interaction with PD-1","volume":"22","author":"Ghiotto","year":"2010","journal-title":"Int Immunol"},{"key":"10.1016\/j.ctrv.2014.12.013_b0050","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.coi.2011.12.009","article-title":"Targeting the PD-1\/B7H1 (PD-L1) pathway to activate antitumor activity","volume":"24","author":"Topalian","year":"2012","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.ctrv.2014.12.013_b0055","doi-asserted-by":"crossref","first-page":"709s","DOI":"10.1158\/1078-0432.CCR-06-1868","article-title":"Implications of B7\u2013H1 expression in clear cell carcinoma of the kidney for prognostication and therapy","volume":"13","author":"Thompson","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2014.12.013_b0060","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2014.32.15_suppl.4585","article-title":"PD-L1 expression in primary clear cell renal cell carcinomas (ccRCCs) and their metastases","volume":"32","author":"Callea","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2014.12.013_b0065","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdu445","article-title":"PD-L1 expression in non-clear cell renal cell carcinoma","author":"Choueiri","year":"2014","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.ctrv.2014.12.013_b0070","doi-asserted-by":"crossref","first-page":"166","DOI":"10.7150\/jca.8167","article-title":"PD-L1 expression in clear cell renal cell carcinoma: an analysis of nephrectomy and sites of metastases","volume":"5","author":"Jilaveanu","year":"2014","journal-title":"J Cancer"},{"issue":"7","key":"10.1016\/j.ctrv.2014.12.013_b0075","doi-asserted-by":"crossref","first-page":"3381","DOI":"10.1158\/0008-5472.CAN-05-4303","article-title":"Tumor B7\u2013H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up","volume":"66","author":"Thompson","year":"2006","journal-title":"Cancer Res"},{"issue":"7","key":"10.1016\/j.ctrv.2014.12.013_b0080","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1158\/1078-0432.CCR-10-0250","article-title":"Identification of a soluble form of B7\u2013H1 that retains immunosuppressive activity and is associated with aggressive renal cell carcinoma","volume":"17","author":"Frigola","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2014.12.013_b0085","first-page":"2120","article-title":"Tumor-infiltrating regulatory T cells are positively correlated with angiogenic status in renal cell carcinoma","volume":"125","author":"Ning","year":"2012","journal-title":"Chin Med J (Engl)"},{"key":"10.1016\/j.ctrv.2014.12.013_b0090","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1097\/CJI.0b013e3181f4c208","article-title":"A decrease of regulatory T cells correlates with overall survival after sunitinib-based antiangiogenic therapy in metastatic renal cancer patients","volume":"33","author":"Adotevi","year":"2010","journal-title":"J Immunother"},{"key":"10.1016\/j.ctrv.2014.12.013_b0095","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1002\/ijc.25674","article-title":"Sorafenib reduces the percentage of tumour infiltrating regulatory T cells in renal cell carcinoma patients","volume":"129","author":"Desar","year":"2011","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ctrv.2014.12.013_b0100","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1186\/1471-2407-11-505","article-title":"Phase I\u2013II study of everolimus and low-dose oral cyclophosphamide in patients with metastatic renal cell cancer","volume":"11","author":"Huijts","year":"2011","journal-title":"BMC Cancer"},{"issue":"3","key":"10.1016\/j.ctrv.2014.12.013_b0105","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1593\/tlo.13256","article-title":"Tumor-infiltrating PD1-positive lymphocytes and FoxP3-positive regulatory T cells predict distant metastatic relapse and survival of clear cell renal cell carcinoma","volume":"6","author":"Kang","year":"2013","journal-title":"Transl Oncol"},{"issue":"9","key":"10.1016\/j.ctrv.2014.12.013_b0110","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1002\/eji.201344423","article-title":"PD-1 regulates extrathymic regulatory T-cell differentiation","volume":"44","author":"Chen","year":"2014","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.ctrv.2014.12.013_b0115","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s00109-011-0806-7","article-title":"Transcript signature predicts tissue NK cell content and defines renal cell carcinoma subgroups independent of TNM staging","volume":"90","author":"Eckl","year":"2012","journal-title":"J Mol Med"},{"key":"10.1016\/j.ctrv.2014.12.013_b0120","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1007\/s00432-010-0944-2","article-title":"Role of sorafenib and sunitinib in the induction of expressions of NKG2D ligands in nasopharyngeal carcinoma with high expression of ABCG2","volume":"137","author":"Huang","year":"2011","journal-title":"J Cancer Res Clin Oncol"},{"issue":"4","key":"10.1016\/j.ctrv.2014.12.013_b0125","article-title":"Correlation of PDL1 tumor expression and treatment outcomes in patients with renal cell carcinoma (RCC) receiving tyrosine kinase inhibitors: COMPARZ study analysis","volume":"32","author":"Choueiri","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2014.12.013_b0130","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1200\/JCO.2009.26.7609","article-title":"Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmodynamics, and immunologic correlates","volume":"28","author":"Brahmer","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2014.12.013_b0135","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2014.12.013_b0140","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti-PD-L1 antibody in patients with advanced cancer","volume":"366","author":"Brahmer","year":"2012","journal-title":"N Engl J Med"},{"issue":"Suppl.","key":"10.1016\/j.ctrv.2014.12.013_b0145","doi-asserted-by":"crossref","first-page":"4505","DOI":"10.1200\/jco.2013.31.15_suppl.4505","article-title":"Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with metastatic renal cell carcinoma (mRCC)","volume":"31","author":"Cho","year":"2013","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ctrv.2014.12.013_b0150","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa1302369","article-title":"Nivolumab plus ipilimumab in advanced melanoma","volume":"369","author":"Wolchok","year":"2013","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.ctrv.2014.12.013_b0155","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1200\/JCO.2013.53.0105","article-title":"Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab","volume":"32","author":"Topalian","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2014.12.013_b0160","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2014.59.0703","article-title":"Nivolumab for metastatic renal cell carcinoma: results of a randomized phase II trial","author":"Motzer","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2014.12.013_b0165","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2014.32.15_suppl.5012","article-title":"Immunomodulatory activity of nivolumab in previously treated and untreated metastatic renal cell carcinoma (mRCC): biomarker-based results from a randomized clinical trial","volume":"32","author":"Choueiri","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2014.12.013_b0170","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2012.30.15_suppl.2512","article-title":"Phase I study of MK-3475 (anti-PD-1 monoclonal antibody) in patients with advanced solid tumors","volume":"30","author":"Patnaik","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2014.12.013_b0175","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2013.31.15_suppl.3044","article-title":"Clinical and pharmacodynamic (PD) results of a phase I trial with AMP-224 (B7-DC Fc) that binds to the PD-1 receptor","volume":"31","author":"Infante","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2014.12.013_b0180","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2014.32.15_suppl.3002","article-title":"Preliminary data from a multi-arm expansion study of MEDI4736, an anti-PD-L1 antibody","volume":"32","author":"Segal","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2014.12.013_b0185","doi-asserted-by":"crossref","first-page":"104","DOI":"10.2174\/157489112801619719","article-title":"Present and future of tyrosine kinase inhibitors in renal cell carcinoma: analysis of hematologic toxicity","volume":"7","author":"Santoni","year":"2012","journal-title":"Recent Pat Antiinfect Drug Discov"},{"key":"10.1016\/j.ctrv.2014.12.013_b0190","doi-asserted-by":"crossref","first-page":"333","DOI":"10.7150\/jca.2.333","article-title":"Immunological effects of multikinase inhibitors for kidney cancer: a clue for integration with cellular therapies?","volume":"2","author":"Porta","year":"2011","journal-title":"J Cancer"},{"key":"10.1016\/j.ctrv.2014.12.013_b0195","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.intimp.2013.01.006","article-title":"Sorafenib induces autophagy and suppresses activation of human macrophage","volume":"15","author":"Lin","year":"2013","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.ctrv.2014.12.013_b0200","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1111\/j.1442-2042.2009.02377.x","article-title":"Angiogenesis in renal cell carcinoma: the role of tumor-associated macrophages","volume":"16","author":"Toge","year":"2009","journal-title":"Int J Urol"},{"key":"10.1016\/j.ctrv.2014.12.013_b0205","doi-asserted-by":"crossref","first-page":"3526","DOI":"10.1158\/0008-5472.CAN-09-3278","article-title":"Direct and differential suppression of myeloid-derived suppressor cell subsets by sunitinib is compartmentally constrained","volume":"70","author":"Ko","year":"2010","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2014.12.013_b0210","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2014.32.15_suppl.5010","article-title":"Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with sunitinib or pazopanib in patients (pts) with metastatic renal cell carcinoma (mRCC)","volume":"32","author":"Amin","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2014.12.013_b0215","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3003689","article-title":"Colocalization of inflammatory response with B7-H1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape","volume":"4","author":"Taube","year":"2012","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.ctrv.2014.12.013_b0220","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1097\/PPO.0b013e3181eacbd8","article-title":"Gene signature in melanoma associated with clinical activity: a potential clue to unlock cancer immunotherapy","volume":"16","author":"Gajewski","year":"2010","journal-title":"Cancer J"},{"key":"10.1016\/j.ctrv.2014.12.013_b0225","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1038\/nrc3153","article-title":"Novel cancer immunotherapy agents with survival benefit: recent successes and next steps","volume":"11","author":"Sharma","year":"2011","journal-title":"Nat Rev Cancer"},{"issue":"8","key":"10.1016\/j.ctrv.2014.12.013_b0230","doi-asserted-by":"crossref","first-page":"viii35","DOI":"10.1093\/annonc\/mds261","article-title":"Emerging immunotherapies for renal cell carcinoma","volume":"23","author":"Escudier","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2014.12.013_b0235","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.hoc.2011.04.010","article-title":"Immunotherapy for renal cell carcinoma","volume":"25","author":"Rosenblatt","year":"2011","journal-title":"Hematol Oncol Clin North Am"},{"issue":"Suppl.","key":"10.1016\/j.ctrv.2014.12.013_b0240","article-title":"Allogeneic partially HLA-matched dendritic cells (DC) as a vaccine in metastatic renal cell cancer (mRCC): final analysis of a clinical phase I\/II study","volume":"30","author":"Fl\u00f6rcken","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2014.12.013_b0245","unstructured":"Argos Therapeutics. New phase 2 data showing Arcelis\u2122 immunotherapy AGS-003 in combination with sunitinib improves progression-free survival (PFS) in patients with advanced renal cell carcinoma (RCC). <www.argostherapeutics.com>."},{"key":"10.1016\/j.ctrv.2014.12.013_b0250","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S0140-6736(08)60697-2","article-title":"An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial","volume":"372","author":"Wood","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2014.12.013_b0255","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1007\/s00262-011-0993-7","article-title":"MVA-5T4-induced immune responses are an early marker of efficacy in renal cancer patients","volume":"60","author":"Harrop","year":"2011","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.ctrv.2014.12.013_b0260","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2010.28.15_suppl.4529","article-title":"Results of a randomized phase II study investigating multipeptide vaccination with IMA901 in advanced renal cell carcinoma (RCC)","volume":"28","author":"Reinhardt","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2014.12.013_b0265","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1146\/annurev.immunol.19.1.565","article-title":"CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy","volume":"19","author":"Chambers","year":"2001","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.ctrv.2014.12.013_b0270","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1097\/CJI.0b013e318156e47e","article-title":"Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis","volume":"30","author":"Yang","year":"2007","journal-title":"J Immunother"},{"key":"10.1016\/j.ctrv.2014.12.013_b0275","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2014.32.15_suppl.4504","article-title":"Phase I study of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mRCC)","volume":"32","author":"Hammers","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2014.12.013_b0280","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1097\/01.cji.0000175468.19742.10","article-title":"Inability of a fusion protein of IL-2 and diphtheria toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to eliminate regulatory T lymphocytes in patients with melanoma","volume":"28","author":"Attia","year":"2005","journal-title":"J Immunother"},{"key":"10.1016\/j.ctrv.2014.12.013_b0285","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1097\/CJI.0b013e3181e4752e","article-title":"A pilot study of denileukin diftitox (DD) in combination with high-dose interleukin-2 (IL-2) for patients with metastatic renal cell carcinoma (RCC)","volume":"33","author":"Atchison","year":"2010","journal-title":"J Immunother"},{"key":"10.1016\/j.ctrv.2014.12.013_b0290","doi-asserted-by":"crossref","first-page":"4450","DOI":"10.1158\/0008-5472.CAN-05-2728","article-title":"Soluble human LAG-3 molecule amplifies the in vitro generation of type 1 tumor-specific immunity","volume":"66","author":"Casati","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2014.12.013_b0295","doi-asserted-by":"crossref","first-page":"6225","DOI":"10.1158\/1078-0432.CCR-09-0068","article-title":"A phase I pharmacokinetic and biological correlative study of IMP321, a novel MHC class II agonist, in patients with advanced renal cell carcinoma","volume":"15","author":"Brignone","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2014.12.013_b0300","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1093\/jnci\/85.8.622","article-title":"Prospective randomized trial of highdose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer","volume":"85","author":"Rosenberg","year":"1993","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ctrv.2014.12.013_b0305","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/j.1442-2042.1998.tb00227.x","article-title":"Adoptive immunotherapy of patients with metastatic renal cell cancer using lymphokine-activated killer cells, interleukin-2 and cyclophosphamide: long-term results","volume":"5","author":"Tomita","year":"1998","journal-title":"Int J Urol"},{"key":"10.1016\/j.ctrv.2014.12.013_b0310","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/BF01676706","article-title":"Increased LAK and T cell activation in responding renal cell carcinoma patients after low dose cyclophosphamide, IL-2 and alpha-IFN","volume":"12","author":"Wersall","year":"1995","journal-title":"Med Oncol"},{"key":"10.1016\/j.ctrv.2014.12.013_b0315","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1056\/NEJM198512053132327","article-title":"Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer","volume":"313","author":"Rosenberg","year":"1985","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2014.12.013_b0320","first-page":"4199","article-title":"Clinical results and characterization of tumor-infiltrating lymphocytes with or without recombinant interleukin 2 in human metastatic renal cell carcinoma","volume":"51","author":"Bukowski","year":"1991","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2014.12.013_b0325","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/S0140-6736(89)91609-7","article-title":"Tumour-infiltrating lymphocytes and interleukin-2 in treatment of advanced cancer","volume":"1","author":"Kradin","year":"1989","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2014.12.013_b0330","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1089\/cbr.2004.19.730","article-title":"Tumor-infiltrating lymphocytes and interleukin-2: dose and schedules of administration in the treatment of metastatic cancer","volume":"19","author":"Dillman","year":"2004","journal-title":"Cancer Biother Radiopharm"},{"key":"10.1016\/j.ctrv.2014.12.013_b0335","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1200\/JCO.1999.17.8.2521","article-title":"Multicenter, randomized, phase III trial of CD8(+) tumor-infiltrating lymphocytes in combination with recombinant interleukin-2 in metastatic renal cell carcinoma","volume":"17","author":"Figlin","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2014.12.013_b0340","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1200\/JCO.1995.13.8.1939","article-title":"Adoptive immunotherapy with tumor infiltrating lymphocytes and interleukin-2 in patients with metastatic malignant melanoma and renal cell carcinoma: a pilot study","volume":"13","author":"Goedegebuure","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2014.12.013_b0345","first-page":"185","article-title":"CD4 TIL (Tumor Infiltrating Lymphocytes) induce complete response in patients treated with IL-2 (Interleukin-2). Preliminary study","volume":"100","author":"Thiounn","year":"1994","journal-title":"J Urol (Paris)"},{"key":"10.1016\/j.ctrv.2014.12.013_b0350","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/S1470-2045(04)01568-2","article-title":"Allogeneic stem-cell transplantation for renal-cell cancer","volume":"5","author":"Gommersall","year":"2004","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.ctrv.2014.12.013_b0355","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1158\/1078-0432.CCR-08-1825","article-title":"Antiprogrammed death-1 synergizes with granulocyte macrophage colony-stimulating factor\u2013secreting tumor cell immunotherapy providing therapeutic benefit to mice with established tumors","volume":"15","author":"Li","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2014.12.013_b0360","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1158\/1535-7163.MCT-11-0677","article-title":"Immunotherapy of cancer with 4\u20131BB","volume":"11","author":"Vinay","year":"2012","journal-title":"Mol Cancer Ther"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737214002187?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737214002187?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,28]],"date-time":"2020-08-28T17:49:21Z","timestamp":1598636961000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737214002187"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2]]},"references-count":72,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,2]]}},"alternative-id":["S0305737214002187"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2014.12.013","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2015,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PD-1 blockade therapy in renal cell carcinoma: Current studies and future promises","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2014.12.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}